Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.00
+0.09 (0.76%)
At close: Feb 11, 2026, 4:00 PM EST
12.00
0.00 (0.00%)
After-hours: Feb 11, 2026, 7:58 PM EST
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$142,749
Profits / Employee
-$1,106,218
Market Cap
1.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | 312 | 42 | 15.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,500 |
| Novavax | 952 |
| Immatics | 645 |
| Relay Therapeutics | 188 |
| Monte Rosa Therapeutics | 147 |
| AnaptysBio | 136 |
| Kodiak Sciences | 123 |
| AtaiBeckley | 54 |
NTLA News
- 5 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 - Seeking Alpha
- 15 days ago - Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder - Benzinga
- 15 days ago - US FDA lifts clinical hold on Intellia's nerve disease trail - Reuters
- 4 weeks ago - Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - The Short List — Top 10 Most Shorted Stocks Right Now - Benzinga
- 3 months ago - Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire